Close Menu

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed a UK distribution agreement for its SelectMDx prostate cancer test with Lab21.

Under the terms of the deal, Lab21 will serve as a non-exclusive distributor of the test in the UK, and send liquid biopsy samples to MDxHealth's clinical diagnostic lab in The Netherlands for analysis. Lab21 will reimburse MDxHealth for all testing services performed.

Additional terms were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jun
13

Ribosomal ribonucleic acid (rRNA) accounts for up to 99 percent of the total RNA depending on the cell type. 

Jun
18
Sponsored by
ArcherDX

This webinar will discuss background and clinical genomics of NTRK fusion detection in cancer. NTRK fusions are the focus of new therapeutic options, but clonal and subclonal lesions are notoriously difficult to detect. 

Jun
19

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.